|
|||||
|
|
Phase III,efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone |
|
| Authors: | Steven G. Terra PharmD Kristen Focht BS MBA Melanie Davies MD Juan Frias MD Giuseppe Derosa MD PhD Amanda Darekar PhD Gregory Golm PhD Jeremy Johnson BS Didier Saur MD Brett Lauring MD PhD Sam Dagogo‐Jack MD |
| Affiliation: | 1. Pfizer, Andover, Massachusetts;2. Pfizer, Collegeville, Pennsylvania;3. Diabetes Research Centre, University of Leicester, Leicester, UK;4. National Research Institute, Los Angeles, California;5. University of Pavia and IRCCS Policlinico San Matteo Foundation, Pavia, Italy;6. Pfizer Ltd, Tadworth, UK;7. Merck & Co., Inc., Kenilworth, New Jersey;8. Pfizer, Paris, France;9. University of Tennessee Health Sciences Center, Memphis, Tennessee |
| Abstract: | |
| Keywords: | ertugliflozin monotherapy SGLT2 type 2 diabetes mellitus |